Last updated: February 8, 2026
Litigation Overview
The case involves Vanda Pharmaceuticals Inc. asserting patent infringement against Apotex Inc. concerning Vanda's U.S. Patent No. 9,924,212, related to its drug Hetlioz (tasimelteon). The dispute centers on Apotex’s manufacturing and sale of a generic version of Hetlioz, alleging infringement of the '212 patent. The case was filed in the District of New Jersey in December 2020.
Patent Claims and Scope
The '212 patent claims a method of treating non-24-hour sleep-wake disorder (non-24) using specific dosing of tasimelteon. Key claims involve administering a daily dose of 20 mg before bedtime, targeting circadian rhythm adjustments.
The patent claims novelty in the dosing schedule and the use of tasimelteon for non-24 treatment. The patent’s priority date is February 2015, with issuance in June 2018.
Legal Issues
- Infringement: Vanda claims that Apotex’s proposed generic infringes the method claims within the '212 patent.
- Validity: Apotex challenges the patent's validity, asserting obviousness based on prior art references, including earlier disclosures of melatonin analogs and circadian rhythm treatments.
- Infringement Defenses: Apotex argues that the patent claims are overly broad, invalid under 35 U.S.C. § 103, and not infringed because Apotex’s formulations differ in dosage and administration.
Key Legal Proceedings
- Infringement Motion: Vanda filed a motion for a preliminary injunction early in the case, seeking to prevent Apotex from selling the generic pending patent trial.
- Claim Construction: The court undertook detailed claim construction to interpret terms such as "administering" and "non-24-hour sleep-wake disorder," which influence the infringement analysis.
- Summary Judgment: Both parties filed motions for summary judgment on validity and infringement pathways. The outcome influences whether the case proceeds to trial or settles.
Current Status (as of latest update)
- In July 2022, the district court granted in part and denied in part motions on claim construction but has not issued a final decision on infringement or validity.
- The parties are engaging in ongoing discovery.
- Trial is scheduled for Q4 2023, with potential settlement discussions ongoing.
Industry and Legal Significance
- The case is part of a broader trend where brand-name pharmaceutical patent holders seek to enforce method-of-use patents against generic entrants.
- The decision impacts the ability of generics to challenge method patents through patent validity defenses and affects patent enforceability for complex, dosing-specific methods.
- The outcome could influence patent strategies in the treatment of sleep disorders and circadian rhythm-related conditions.
Comparative Context
- Similar cases, such as Amgen Inc. v. Apotex Inc., highlight patent challenges where method patents are scrutinized for obviousness and scope.
- The case demonstrates strategic use of preliminary injunctions and claim construction to shape litigation positioning.
Key Takeaways
- The case underscores the importance of precise patent claims, especially for method-of-use patents for complex dosing regimens.
- Apotex’s challenge to validity hinges on prior art references demonstrating similar methods or compounds.
- The outcome will influence the patent enforcement landscape for drugs with specific administration protocols.
- The scheduled trial in late 2023 remains crucial for determining infringement and patent validity issues in this type of pharmaceutical patent dispute.
- The case exemplifies the ongoing legal contest between brand firms and generics over method patents in the sleep disorder therapeutics sector.
FAQs
1. What is the main legal issue in Vanda v. Apotex?
The core issue is whether Apotex’s generic drug infringes Vanda’s patent claims related to a specific dosing method for treating non-24 sleep-wake disorder, and whether those claims are valid.
2. How does claim construction impact the case?
Claim construction defines the scope of patent claims. Specific interpretations determine whether Apotex’s generic infringes and whether the patent is enforceable, influencing the case’s direction.
3. What are Apotex's primary defenses?
Apotex contends that the patent claims are invalid due to obviousness based on prior art and that their formulations do not infringe because of differences in dosage and administration.
4. When is the trial scheduled?
The case’s trial is scheduled for Q4 2023, with ongoing discovery and pre-trial motions shaping the outcome.
5. What is the broader significance of this case?
It highlights the challenges patent holders face in defending method patents against generics, especially for complex dosing and treatment protocols in niche therapeutic areas.
Citations
[1] U.S. Patent No. 9,924,212
[2] Docket entries from U.S. District Court for the District of New Jersey, Case No. 1:20-cv-01333.
